Company Overview
More
China Biopharmaceutical Co., Ltd. is an investment holding company mainly engaged in pharmaceutical business. The company operates through three business divisions. The modern preparation and western medicine branch of traditional Chinese medicine is engaged in the production, sales and distribution of modern preparation products of traditional Chinese medicine and western medicine products. The investment division is engaged in long-term and short-term investment business. Other divisions are mainly engaged in R & D activities, providing services to third parties and related medical and hospital businesses. Through its subsidiaries, the company is also engaged in holding property, selling health food, optometry and optometry, as well as retail and wholesale optometry and hearing products.
CEO： Qirun Xie
Market： Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
01177 SINO BIOPHARM
4.300+0.050+1.18%
YOY
Do not show
(FY)2021/12/31(Q6)2021/06/30(Q3)2021/03/31(FY)2020/12/31
Assets
Current assets
Inventory
3.07%
1.94B
-3.94%
1.73B
0.36%
1.81B
13.35%
1.88B
Accounts receivable
44.84%
4.22B
--
--
--
--
--
2.91B
Related party payments receivable
222.43%
404.77M
-20.27%
115.41M
-19.41%
116.79M
-17.19%
125.54M
Advance deposits and other receivables
-28.48%
1.72B
-28.59%
6.46B
-40.27%
6.27B
-65.25%
2.4B
Cash and equivalents
-6.13%
10.57B
-53.03%
8.03B
-50.79%
7.93B
-5.47%
11.26B
Financial assets at fair value-current assets
10.41%
4.66B
21.81%
2.42B
36.48%
2.4B
167.52%
4.22B
Special items of current assets
--
--
16.87%
5.06B
24.41%
3.25B
--
--
Total current assets
3.11%
23.5B
-30.78%
23.81B
-33.86%
21.79B
-8.51%
22.79B
Non-current assets
Property, plant and equipment
4.13%
7.15B
-2.29%
7.08B
0.93%
7.06B
7.7%
6.87B
Investment property
128.68%
705.63M
-47.6%
293.93M
-46.52%
303.41M
-45.23%
308.56M
Advance payment
57.78%
602.18M
592.73%
3.68B
651.77%
3.72B
-7.92%
381.65M
Associated company interest
182.47%
14.27B
--
--
--
--
--
5.05B
Fixed time deposit-non-current assets
68.54%
4.97B
--
--
--
--
--
2.95B
Stock investment
-0.14%
1.99B
--
--
--
--
--
1.99B
Financial assets at fair value-non-current assets
2.01%
3.94B
--
--
--
3.87B
--
3.87B
Intangible assets
15.06%
1.06B
-87.68%
915.74M
-88.69%
848.79M
-30.17%
924.71M
Goodwill
628.62%
647.93M
-93.48%
906.03M
-93.59%
890.83M
0%
88.93M
Deferred tax assets
-27.73%
334.87M
38.8%
695.86M
-21.97%
464.06M
-16.86%
463.37M
Special items of non-current assets
-10.52%
1.36B
565.07%
18.82B
286.04%
10.2B
-53.51%
1.52B
Total non-current assets
51.7%
37.04B
-4.58%
32.39B
-18.79%
27.36B
93.76%
24.42B
Total assets
28.24%
60.54B
-17.76%
56.21B
-26.24%
49.15B
25.85%
47.21B
Liabilities
Current liabilities
Accounts payable
-13.07%
1.69B
-42.15%
1.62B
-20.47%
2.16B
7.65%
1.95B
Tax payable
66.66%
101.17M
90.59%
252.4M
-57.36%
134.82M
-68.03%
60.7M
Amounts payable to associated parties-current liabilities
--
237.66M
--
--
--
--
--
--
Other payables and accrued expenses
-8.51%
6.73B
7.03%
7.77B
2.72%
6.84B
35.33%
7.35B
Bank loans and overdrafts
319.92%
6.52B
493.25%
1.82B
1295.46%
1.21B
132.89%
1.55B
Financial lease liabilities-current liabilities
124.65%
64.47M
-42.82%
21.16M
-35.14%
15.72M
24.35%
28.7M
Total current liabilities
40.22%
15.35B
9.02%
11.49B
5.69%
10.36B
34.72%
10.94B
Net current assets
-31.16%
8.16B
-48.35%
12.33B
-50.61%
11.43B
-29.42%
11.85B
Total assets less current liabilities
24.63%
45.2B
-22.65%
44.72B
-31.75%
38.79B
23.39%
36.27B
Non-current liabilities
Long-term bank loan
-94.03%
413.34M
-22.78%
6.27B
-13.7%
7.01B
-12.21%
6.92B
Financial lease liabilities-non-current liabilities
20.8%
319.95M
603.85%
291.36M
537.06%
263.71M
541.78%
264.86M
Deferred tax liability
413.59%
881.59M
-50.96%
773.5M
-78.96%
326.03M
-59.45%
171.65M
Deferred income-non-current liabilities
10.89%
674.45M
85.32%
579.92M
78.32%
578.16M
26.54%
608.2M
Convertible notes and bonds
-15.79%
4.95B
-8.97%
5.69B
0.81%
5.76B
--
5.88B
Special items of non-current liabilities
--
227.98M
--
--
--
--
--
--
Total non-current liabilities
-46.06%
7.47B
-16.54%
13.61B
-11.51%
13.94B
56.82%
13.85B
Total liabilities
-7.97%
22.81B
-6.51%
25.1B
-4.92%
24.3B
46.23%
24.79B
Total assets less total liabilities
68.29%
37.73B
-25.04%
31.11B
-39.51%
24.85B
9.04%
22.42B
Total equity and non-current liabilities
24.63%
45.2B
-22.65%
44.72B
-31.75%
38.79B
23.39%
36.27B
Equity
Share capital
-0.11%
415.44M
49.44%
415.9M
49.43%
415.9M
49.36%
415.9M
Reserve
81.92%
30.57B
-22.18%
24.63B
-41.21%
18.72B
11.39%
16.8B
Legal reserve
81.92%
30.57B
-22.18%
24.63B
-41.21%
18.72B
11.39%
16.8B
Special items of shareholders' rights and interests
-46.69%
-689.35M
-13.83%
-469.94M
-13.83%
-469.94M
-13.83%
-469.94M
Shareholders' Equity
80.87%
30.29B
-22.02%
24.58B
-41.13%
18.67B
12.03%
16.75B
Non-controlling interest
31.12%
7.44B
-34.59%
6.53B
-34.03%
6.19B
1.08%
5.67B
Total equity
68.29%
37.73B
-25.04%
31.11B
-39.51%
24.85B
9.04%
22.42B
Total equity and total liabilities
28.24%
60.54B
-17.76%
56.21B
-26.24%
49.15B
25.85%
47.21B
Currency Unit
CNYCNYCNYCNY
Accounting Standards
HKASHKASHKASHKAS
Audit Opinions
Unqualified Opinion----Unqualified Opinion
Auditor
Ernst & Young accounting firm----Ernst & Young accounting firm
Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.
The MOM data from the Quarterly report，MOM=(current period - last period)/last period *100%